BNTX

BioNTech SE ADR

85.86

Nov 05 • 3:59 PM ET -4.84 (-5.34%)

86.50

Aftermarket • 7:59 PM ET +0.64 (0.75%)

Healthcare Biotechnology Germany Large NASD

Peers: MRNA SMMT GMAB ARCT NVAX ONC REGN PFE PCVX IOVA

| Held by: FBT IBB FNDF IDNA SPDW BBH BBEU QQQJ IALT BBIN

Scroll to Statements

Index	-
Market Cap	21.57B
Enterprise Value	6.31B
Income	-1.72B
Sales	2.80B
Book/sh	81.14
Cash/sh	63.03
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jun 02, 2022
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7807
IPO	Oct 10, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	7.70
P/B	1.06
P/C	1.36
P/FCF	-
EV/EBITDA	-
EV/Sales	2.25
Quick Ratio	8.52
Current Ratio	8.55
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-6.87
EPS next Y	-6.30
EPS next Q	-1.90
EPS this Y	-21.21%
EPS next Y	1.44%
EPS next 5Y	3.38%
EPS past 3/5Y	- -
Sales past 3/5Y	-43.74% 42.57%
EPS Y/Y TTM	-160.57%
Sales Y/Y TTM	-20.72%
EPS Q/Q	702.08%
Sales Q/Q	-16.44%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	8.92% 24.48%

Insider Own	0.43%
Insider Trans	-44.27%
Inst Own	18.87%
Inst Trans	-0.18%
ROA	-7.17%
ROE	-8.22%
ROIC	-8.42%
Gross Margin	50.99%
Oper. Margin	-61.20%
Profit Margin	-61.40%
SMA20	-3.96%
SMA50	-9.75%
SMA200	-11.17%
Trades

Shs Outstand	247.93M
Shs Float	246.87M
Short Float	0.92%
Short Ratio	1.82
Short Interest	2.27M
52W High	124.00 -30.76%
52W Low	79.52 7.97%
Volatility	3.72% 3.23%
ATR (14)	3.16
RSI (14)	39.42
Beta	1.32
Rel Volume	0.96
Avg Volume	1.25M
Volume	1,191,075

Perf Week	-3.67%
Perf Month	-9.86%
Perf Quarter	-8.34%
Perf Half Y	-7.70%
Perf YTD	-9.81%
Perf Year	-16.99%
Perf 3Y	-10.36%
Perf 5Y	-59.84%
Perf 10Y	-
Recom	1.79
Target Price	115.38
Prev Close	90.70
Price	85.86
Change %	-5.34%

Consensus

Buy

Avg. Price Target

$115.38

Implied Upside

+34.4%

Analysts17incl. previous ratings

Rating Distribution12 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 08, 2026	Initiated	AArgus	Hold
Sep 08, 2026	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$105	+22.3%
May 27, 2026	Upgrade	UUBS	Neutral → Buy	$135	+57.2%
May 22, 2026	Initiated	BBernstein	Mkt Perform	$96	+11.8%
Feb 02, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$113	+31.6%
Jan 16, 2026	Upgrade	GGoldman	Neutral → Buy	$142	+65.4%
Jun 05, 2025	Reiterated	HH.C. Wainwright	Buy	$134 → $145	+68.9%
May 29, 2025	Initiated	GGoldman	Neutral	$110	+28.1%
Mar 13, 2025	Initiated	CCitigroup	Buy	$145	+68.9%
Jan 10, 2025	Initiated	TTruist	Buy	$172	+100.3%
Dec 11, 2024	Initiated	WWells Fargo	Overweight	$170	+98.0%
Dec 02, 2024	Reiterated	BBMO Capital Markets	Outperform
Nov 19, 2024	Upgrade	EEvercore ISI	In-line → Outperform	$110 → $125	+45.6%
Nov 19, 2024	Initiated	BBerenberg	Buy	$130	+51.4%
Nov 08, 2024	Upgrade	GGoldman	Neutral → Buy	$90 → $137	+59.6%
Sep 24, 2024	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$93 → $145	+68.9%
Sep 17, 2024	Upgrade	JJefferies	Hold → Buy	$96 → $150	+74.7%
Sep 16, 2024	Upgrade	JJP Morgan	Underweight → Neutral	$91 → $125	+45.6%
Aug 07, 2024	Upgrade	DDeutsche Bank	Hold → Buy	$95	+10.6%
Aug 02, 2024	Upgrade	HHSBC Securities	Hold → Buy

Nov-03-26 10:30AM	BioNTech Crushes Estimates On A BMS-Boosted Quarter, But Late-Stage Setbacks Leave Shares Near Their Lows (Earnings Whispers)
07:20AM	Pfizer Finds Life Beyond the Pandemic as Earnings Top Estimates (Barrons.com)
06:45AM	BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Oct-26-26 04:11PM	BioNTech Heads Into Its Key Vaccine Quarter With A Lowered Bar And Shaken Confidence (Earnings Whispers)
05:00AM	BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer (GlobeNewswire)
03:30AM	Loading…
Oct-25-26 03:30AM	BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy (GlobeNewswire)
Oct-23-26 10:06AM	Moderna's Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure (Barrons.com)
Oct-22-26 06:45AM	BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer (GlobeNewswire)
Oct-20-26 06:45AM	BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 (GlobeNewswire)
Oct-19-26 06:45AM	BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 (GlobeNewswire)
Oct-13-26 08:27AM	BioNTech Shares Fall 5% as BNT113 Cancer Trial Misses Progression-Free Survival Endpoint (InvestorsHub) -7.13%
08:19AM	BioNTech stock falls after cancer trial misses key endpoint (Investing.com)
06:45AM	BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer (GlobeNewswire)
Sep-28-26 10:06AM	BioNTech to Close Manufacturing Sites in Germany and Singapore After Sale Process Ends (InvestorsHub)
Sep-23-26 12:53PM	Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next (Barrons.com)
01:12PM	Loading…
Sep-21-26 01:12PM	Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test. (Barrons.com)
Sep-14-26 10:12AM	BioNTech Shares Rise 6.4% After Updated Gotistobart Lung Cancer Trial Data (InvestorsHub)
04:00AM	BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients (GlobeNewswire)
Sep-08-26 07:28AM	BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts (Investing.com)
06:18AM	BioNTech Shares Fall After BMO Downgrade and Price Target Cut (InvestorsHub)
Aug-28-26 02:02PM	BioNTech Kills a Cancer Trial Roche Helped Build (GuruFocus.com) -8.37%
10:46AM	BioNTech Stock Falls on Cancer Vaccine Setback (Barrons.com)
10:09AM	BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast (Investing.com)
Aug-27-26 04:30PM	Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine (Business Wire)
Aug-21-26 02:54PM	Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech's Biggest Players (Barrons.com) +5.12%
01:44PM	Why Moderna's mRNA Cancer Drug Hype Has Gone Too Far (Barrons.com)
Aug-20-26 12:43PM	Moderna's Cancer Vaccine: Are Investors Putting The Cart Before The Horse? (Investor's Business Daily)
05:30AM	BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 (GlobeNewswire)
Aug-19-26 03:38PM	Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally (MarketWatch) +21.96%
02:54PM	BioNTech Stock Surges 20% on Moderna Cancer Vaccine Win. Why the Gains Could Fade. (Barrons.com)
08:28AM	Loading…
08:28AM	Moderna stock is soaring in premarket after encouraging trial of cancer vaccine (MarketWatch)
Aug-04-26 03:01PM	BioNTech SE (BNTX) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress Offsets Revenue ... (GuruFocus.com)
07:12AM	Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings (Barrons.com)
06:45AM	BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Aug-03-26 05:00AM	BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer (GlobeNewswire)
Jul-30-26 08:40AM	EU greenlights Pfizer and BioNTech's new COVID vaccine (InvestorsHub)
Jul-29-26 04:30PM	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union (Business Wire)
Jul-21-26 06:45AM	BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026 (GlobeNewswire)
Jul-07-26 03:22PM	Former Pfizer Building Is Crumbling-Just as the Stock Has (Barrons.com)
Jun-18-26 10:34AM	VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 (Exec Edge)
May-30-26 02:15PM	Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial (GlobeNewswire)
May-27-26 11:07AM	This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative. (Barrons.com)
May-22-26 05:00AM	BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting (GlobeNewswire)
May-20-26 03:29PM	JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms (Investing.com)
May-15-26 04:15PM	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 (GlobeNewswire)
May-07-26 06:45AM	BioNTech Announces New ADS Repurchase Program (GlobeNewswire)
May-05-26 09:54AM	BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. (Barrons.com)
07:26AM	BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push (The Wall Street Journal)
06:45AM	BioNTech Announces First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-21-26 06:45AM	BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 (GlobeNewswire) +6.09%
Apr-11-26 07:00AM	BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer (GlobeNewswire)
Mar-24-26 06:45AM	BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer (GlobeNewswire)
Mar-16-26 04:03PM	Covid Vaccine Maker BioNTech Offers Cheap Biotech Play Given Huge Cash Reserves (Barrons.com)
Mar-15-26 05:05PM	Man's dog was riddled with tumors and dying. He used ChatGPT to design a custom cancer vaccine, stunning researchers (Moneywise)
Mar-11-26 05:55AM	BioNTech price target lowered to $130 from $145 at Citi (TipRanks) +8.28%
Mar-10-26 04:42PM	BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here? (Barchart) -17.88%
04:20PM	BioNTech Cofounders To Step Down. Stock Crumbles. (Investor's Business Daily)
03:39PM	BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls (Benzinga)
03:00PM	BioNTech SE (BNTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue Challenges (GuruFocus.com)
11:01AM	Kohl's Q4 sales miss, EV maker NIO reports first quarterly profit (Yahoo Finance Video)
10:01AM	BioNTech Tumbles as Founding Duo Plan Leave to Start New Firm (Bloomberg)
09:24AM	BioNTech Reports Earnings. That's Not Why the Stock Is Down 17%. (Barrons.com)
08:40AM	BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture (Benzinga)
07:40AM	Scientists behind COVID-19 vaccine will depart BioNTech (MarketWatch)
07:18AM	BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. (Barrons.com)
06:50AM	BioNTech Cofounders to Leave to Form New Company (The Wall Street Journal)
06:45AM	BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
06:33AM	BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 (GlobeNewswire)
Mar-09-26 04:17PM	Oracle, Ulta, Adobe, More Stocks With Earnings This Week (Benzinga)
Mar-05-26 12:37PM	Is BioNTech SE (BNTX) A Good Stock To Buy Now? (Insider Monkey)
Mar-04-26 08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
Feb-25-26 09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire)
Feb-24-26 06:45AM	BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026 (GlobeNewswire)
Feb-22-26 09:05AM	Moderna, Coinbase, And Global Payments Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio? (Benzinga)
Feb-20-26 11:02AM	Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot (Benzinga)
Feb-19-26 03:43AM	BioNTech SE (BNTX) Rallying on Solid Oncology Strategy (Insider Monkey)
Feb-18-26 11:20AM	Moderna stock surges as FDA reverses course, agrees to review new flu shot (Yahoo Finance)
Feb-09-26 10:29AM	BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? (Zacks)
Feb-03-26 11:32AM	Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data (Zacks)
Feb-02-26 09:47AM	Palantir upgraded, Best Buy downgraded: Wall Street's top analyst calls (The Fly)
08:10AM	Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings? (Zacks)
Jan-31-26 06:09AM	Goldman Sachs Picks 2 Stocks That Let Investors Buy the Dip or Ride the Momentum (TipRanks)
Jan-30-26 08:49AM	Will BMY's Oncology Collaborations Drive Its Next Growth Phase? (Zacks)
07:58AM	Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? (Zacks)
02:07AM	Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline (Insider Monkey)
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
09:13AM	BioNTech SE (BNTX): A Bull Case Theory (Insider Monkey)
08:00AM	BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer (GlobeNewswire)
Jan-27-26 01:35PM	2 Biotech Stocks Set to Rebound in 2026 (Motley Fool)
05:38AM	Pfizers CEO on leading after a moonshotand making deals with Trump (Fortune)
05:32AM	What Are Wall Street Analysts' Target Price for Pfizer Stock? (Barchart)
Jan-22-26 10:28AM	BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? (Zacks)
01:03AM	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality (Reuters)
Jan-20-26 01:41PM	BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? (Zacks)
Jan-19-26 09:01AM	What to Expect From Pfizer's Non-Oncology Business in Q4? (Zacks)
Jan-16-26 09:32AM	Seagate upgraded, Tractor Supply downgraded: Wall Street's top analyst calls (The Fly)
Jan-14-26 07:59AM	JPM26: BioNTech gears up for multiproduct oncology status by 2030 (Pharmaceutical Technology)
04:04AM	BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan (MarketBeat)
Jan-12-26 06:45AM	BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 09:16AM	BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sahin Ugur	Chief Executive Officer	Oct 09 '26	Sale	95.37	36,209	3,453,372	0	Oct 09 04:47 PM
Sahin Ugur	Chief Executive Officer	Oct 08 '26	Sale	92.31	27,000	2,492,483	36,209	Oct 09 04:47 PM
Sahin Ugur	Chief Executive Officer	Oct 07 '26	Sale	95.86	24,000	2,300,633	63,209	Oct 07 05:14 PM
Sahin Ugur	Chief Executive Officer	Oct 05 '26	Sale	97.23	72,000	7,000,646	108,209	Oct 06 04:59 PM
Sahin Ugur	Chief Executive Officer	Oct 06 '26	Sale	96.81	21,000	2,032,995	87,209	Oct 06 04:59 PM
Sahin Ugur	Chief Executive Officer	Oct 01 '26	Sale	97.46	17,000	1,656,745	197,209	Oct 02 04:27 PM
Sahin Ugur	Chief Executive Officer	Oct 02 '26	Sale	96.72	17,000	1,644,323	180,209	Oct 02 04:27 PM
Sahin Ugur	Chief Executive Officer	Sep 29 '26	Sale	98.26	34,000	3,340,809	246,209	Sep 30 04:29 PM
Sahin Ugur	Chief Executive Officer	Sep 30 '26	Sale	98.12	32,000	3,139,850	214,209	Sep 30 04:29 PM
Sahin Ugur	Chief Executive Officer	Sep 28 '26	Sale	98.47	34,000	3,347,919	280,209	Sep 28 05:16 PM
Sahin Ugur	Chief Executive Officer	Sep 25 '26	Sale	98.69	27,000	2,664,581	314,209	Sep 28 05:16 PM
Sahin Ugur	Chief Executive Officer	Sep 24 '26	Sale	98.99	39,000	3,860,661	341,209	Sep 24 04:26 PM
Sahin Ugur	Chief Executive Officer	Sep 23 '26	Sale	99.40	30,000	2,982,081	380,209	Sep 24 04:26 PM
Sahin Ugur	Chief Executive Officer	Sep 22 '26	Sale	100.72	46,000	4,633,037	410,209	Sep 22 05:04 PM
Sahin Ugur	Chief Executive Officer	Sep 21 '26	Sale	97.81	33,000	3,227,720	456,209	Sep 22 05:04 PM
Sahin Ugur	Chief Executive Officer	Sep 17 '26	Sale	98.60	34,000	3,352,342	519,209	Sep 18 04:41 PM
Sahin Ugur	Chief Executive Officer	Sep 18 '26	Sale	96.22	30,000	2,886,729	489,209	Sep 18 04:41 PM
Sahin Ugur	Chief Executive Officer	Sep 15 '26	Sale	96.49	34,000	3,280,636	568,209	Sep 16 04:46 PM
Sahin Ugur	Chief Executive Officer	Sep 16 '26	Sale	96.09	15,000	1,441,340	553,209	Sep 16 04:46 PM
Sahin Ugur	Chief Executive Officer	Sep 11 '26	Sale	96.93	45,000	4,362,021	643,209	Sep 14 04:50 PM
Sahin Ugur	Chief Executive Officer	Sep 14 '26	Sale	99.45	41,000	4,077,315	602,209	Sep 14 04:50 PM
Sahin Ugur	Chief Executive Officer	Sep 10 '26	Sale	96.31	20,500	1,974,287	688,209	Sep 11 05:18 PM
Sahin Ugur	Chief Executive Officer	Sep 08 '26	Sale	99.20	37,000	3,670,518	744,709	Sep 09 05:29 PM
Sahin Ugur	Chief Executive Officer	Sep 09 '26	Sale	97.78	36,000	3,520,145	708,709	Sep 09 05:29 PM
Sahin Ugur	Chief Executive Officer	Sep 03 '26	Sale	102.85	45,000	4,628,232	813,209	Sep 08 04:10 PM
Sahin Ugur	Chief Executive Officer	Sep 04 '26	Sale	103.52	31,500	3,260,823	781,709	Sep 08 04:10 PM
Medine GmbH	Officer	Sep 03 '26	Proposed Sale	103.81	858,209	89,090,676		Sep 03 08:03 AM
Medine GmbH	Officer	May 13 '26	Proposed Sale	93.66	858,209	80,379,855		May 12 06:56 PM
Poetting Sierk	Chief Operating Officer	Apr 22 '26	Sale	110.56	50,000	5,527,960	399,387	Apr 23 04:02 PM
Poetting Sierk	Officer	Mar 11 '26	Proposed Sale	83.89	150,000	12,583,500		Mar 11 08:02 AM
Medine GmbH	Officer	Feb 12 '26	Proposed Sale	109.38	858,209	93,870,900		Feb 12 08:17 AM
Tureci Ozlem	Officer	Nov 28 '25	Proposed Sale	102.70	123,331	12,666,094		Nov 28 07:10 AM
Medine GmbH	Officer	Nov 13 '25	Proposed Sale	111.70	1,114,130	124,448,321		Nov 13 08:23 AM

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Co-FounderDr. Ugur Sahin M.D.

Co-FounderDr. Ozlem Tureci M.D.

CFO & Member of Management BoardMr. Ramon Zapata-Gomez

MDDr. Sierk Potting Ph.D.

Chief Legal & Business Officer and Member of the Management BoardDr. James Timothy Patrick Ryan Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BNTX

BioNTech SE ADR

Upgrade your Finviz experience